A108 USTEKINUMAB IV INDUCTION RESULTS IN CROHN’S DISEASE SYMPTOM IMPROVEMENT WITHIN THE FIRST WEEK IN ANTI-TNF REFRACTORY PATIENTS

BACKGROUND: In both the UNITI-1&2 Crohn’s disease (CD) studies, a single 6mg/kg Ustekinumab (UST) IV infusion showed significantly greater rates of clinical response & remission vs placebo, and significant reductions in CDAI (and >70 pt reduction)(1) by the first post-baseline visit at Wk...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Can Assoc Gastroenterol
Main Authors: Sandborn, W, Yeager, B, Gasink, C, Hoops, T, Gao, L, Wang, Y, Jacobstein, D, Lee, S D, Hanauer, S
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Paper Sessions
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6508147/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.108
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados